Opthea Presents Wet AMD Trial Data at Macula Society Meeting
Ticker: OPTEY · Form: 6-K · Filed: Feb 6, 2025 · CIK: 1815620
Sentiment: neutral
Topics: clinical-trial-data, biotech, regulatory-filing
Related Tickers: OPT
TL;DR
Opthea dropped Phase 3 wet AMD data at Macula Society, big step for drug approval.
AI Summary
Opthea Ltd. (ASX:OPT, NASDAQ:OPT) announced on February 6, 2025, that data from its Phase 3 ShOEnguARD trial for its wet age-related macular degeneration (AMD) therapy, sozinibercept, was featured at the Macula Society Meeting. The presentation highlighted key efficacy and safety data from the trial, which is crucial for potential regulatory submissions.
Why It Matters
The presentation of Phase 3 trial data is a critical step for Opthea as it moves towards potential regulatory approval for its novel wet AMD therapy, potentially impacting the treatment landscape for millions affected by the condition.
Risk Assessment
Risk Level: medium — Clinical trial data presentations are important but do not guarantee regulatory approval or commercial success.
Key Players & Entities
- Opthea Ltd (company) — Registrant
- sozinibercept (drug) — Therapy for wet AMD
- ShOEnguARD trial (clinical_trial) — Phase 3 trial for sozinibercept
- Macula Society Meeting (event) — Venue for data presentation
- February 6, 2025 (date) — Date of filing
FAQ
What specific data from the ShOEnguARD trial was presented at the Macula Society Meeting?
The filing indicates that key efficacy and safety data from the Phase 3 ShOEnguARD trial for sozinibercept was featured, though specific numerical results are not detailed in this 6-K.
What is the significance of presenting data at the Macula Society Meeting for Opthea?
Presenting data at the Macula Society Meeting is significant as it showcases the progress of Opthea's wet AMD therapy, sozinibercept, and is a step towards potential regulatory submissions.
What is the primary indication for Opthea's therapy, sozinibercept?
Sozinibercept is being developed for the treatment of wet age-related macular degeneration (AMD).
What form type is this SEC filing?
This SEC filing is a Form 6-K, which is a Report of Foreign Issuer.
What is Opthea Limited's principal executive office address?
Opthea Limited's principal executive office is located at Level 4, 650 Chapel Street, South Yarra, Victoria, 3141, Australia.
Filing Stats: 148 words · 1 min read · ~1 pages · Grade level 13.3 · Accepted 2025-02-06 06:02:38
Filing Documents
- opt_-_opthea_wet_amd.htm (6-K) — 26KB
- opt-ex99_1.htm (EX-99.1) — 23KB
- img260626642_0.jpg (GRAPHIC) — 151KB
- img260626642_1.jpg (GRAPHIC) — 151KB
- 0000950170-25-014953.txt ( ) — 466KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized. OPTHEA LIMITED (Registrant) By: /s/ Frederic Guerard Name: Frederic Guerard Title: Chief Executive Officer Date: 02/06/2025